Download MendeleyDesign, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.
Almstead, N.G., Bradley, R.S., Pikul, S., De, B., Natchus, M.G., Taiwo, Y.O., Gu, F., Williams, L.E., Hynd, B.A., Janusz, M.J., Dunaway, C.M., Mieling, G.E.(1999) J Med Chem 42: 4547-4562
- PubMed: 10579818
- DOI: https://doi.org/10.1021/jm990330y
- Primary Citation of Related Structures:
1D5J - PubMed Abstract:
The synthesis and enzyme inhibition data for a series of thiazine- and thiazepine-based matrix metalloproteinase (MMP) inhibitors are described. The thiazine- and thiazepine-based inhibitors were discovered by optimization of hetererocyclic sulfonamide-based inhibitors. The most potent series of inhibitors was obtained by modification of the amino acid D-penicillamine. This amino acid provides a gem-dimethyl group on the thiazine or thiazepine ring which has a dramatic effect on the in vitro potency of this series. In particular, the sulfide 4a and the sulfone 5a were potent, broad-spectrum inhibitors of the MMPs with IC(50)'s against MMP-1 of 0.8 and 1.9 nM, respectively. The binding mode of this novel thiazepine-based series of MMP inhibitors was established based on X-ray crystallography of the complex of stromelysin and 4a.
Organizational Affiliation:
Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason-Montgomery Road, Mason, Ohio 45040, USA.
